Diplomat Specialty Pharmacy

27 articles about Diplomat Specialty Pharmacy

• Diplomat, OptumRx Combining to Advance Access to Specialty Pharmacy Care and Infusion Services, Improve Health Outcomes

  12/9/2019

  Combination will provide enhanced specialty and infusion services for patients; help manage growth in high-cost specialty pharmaceuticals

• Diplomat Announces 3rd Quarter Financial Results; Updates 2019 Guidance

  11/12/2019

  3rd Quarter Revenue of $1,301 Million, compared to $1,373 Million, Net Loss of $177 Million, compared to Net Income of $0.2 Million, Adjusted EBITDA of $11.5 Million, compared to $41.9 Million

• Diplomat to Release Third-Quarter 2019 Operating Results Nov. 12

  10/30/2019

  Diplomat Pharmacy, Inc. will release its third-quarter 2019 operating results before market open Tuesday, Nov. 12.

• Diplomat Announces Sale of Certain Assets of Envoy Health Management, LLC to Diligent Health Solutions, LLC

  10/16/2019

  The nation's largest independent provider of specialty pharmacy services sells certain assets to Diligent Health Solutions, LLC

• Diplomat Announces Promotion of David Skomo to Chief Operating Officer of CastiaRx

  10/2/2019

  Following the retirement of Chris Luthin, David Skomo Appointed COO at CastiaRx.

• Diplomat signs exclusive practice-based infusion agreement with Allergy Partners

  8/8/2019

  This innovative agreement forms the nation's first large-scale physician practice-based infusion program.

• Diplomat to Release Second-Quarter 2019 Operating Results August 9

  7/18/2019

  Diplomat Pharmacy, Inc. (NYSE: DPLO), will release its second-quarter 2019 operating results before market open Friday, August 9. A conference call and live webcast will be held at 8:30 a.m. ET.

• Diplomat Launches Empower Ecosystem Patient Support Digital Library

  7/9/2019

  The nation's largest independent specialty pharmacy and infusion services provider launches a digital library of resources and tools for patients and caregivers.

• Diplomat Announces 1st Quarter Financial Results

  5/7/2019

  1st Quarter Revenue of $1,257 Million, compared to $1,342 Million, Net Loss of $14.3 Million, compared to a Net Loss of $0.5 Million, Adjusted EBITDA of $23.1 Million, compared to $39.6 Million

• Diplomat to Release First-Quarter 2019 Operating Results May 7, Participate in Bank of America Merrill Lynch Healthcare Conference May 14

  4/17/2019

  Diplomat Pharmacy, Inc., will release its first-quarter 2019 operating results before market open Tuesday, May 7.

• DPLO CLASS ACTION REMINDER: Hagens Berman Reminds Diplomat Pharmacy (DPLO) of Securities Class Action, Encourages Investors to Contact the Firm

  4/15/2019

  Hagens Berman Sobol Shapiro LLP reminds investors in Diplomat Pharmacy, Inc. of the pending securities class action and the April 25, 2019 Lead Plaintiff deadline.

• Diplomat Expands AdhereTech Relationship as Program Shows Increased Adherence and Persistence

  4/10/2019

  A rollout of the smart-bottle program by the nation's largest independent provider of specialty pharmacy and infusion services showed adherence and persistence improvements for patients using AdhereTech.

• Diplomat Grants Chief Financial Officer Dan Davison Inducement Awards Pursuant to NYSE Rule 303A.08

  4/9/2019

  Diplomat Pharmacy, Inc. announced that the Board of Directors has made certain equity awards to new chief financial officer and treasurer Dan Davison, effective April 8, 2019.

• LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Diplomat Pharmacy, Inc. To Contact The Firm

  3/15/2019

  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Diplomat Pharmacy, Inc. of the April 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

• Diplomat Announces 4th Quarter and 2018 Year End Financial Results; Provides Revised 2019 Guidance

  3/15/2019

  4th Quarter Revenue of $1,361 Million, an increase of 18%, Net (Loss) Income Attributable to Diplomat of $(298.0) Million, compared to $6.5 Million, Adjusted EBITDA of $43.5 Million, an increase of 63%

• Diplomat Appoints Daniel Davison as Chief Financial Officer

  3/15/2019

  The company's board of directors has appointed Dan Davison as chief financial officer and treasurer effective April 8, succeeding Atul Kavthekar.

• Diplomat Announces Details of Rescheduled 2018 Results Conference Call

  3/13/2019

  The nation's largest independent provider of specialty pharmacy and infusion services will discuss Q4 and year-end 2018 results, as well as 2019 guidance on a conference call March 15.

• (DPLO) Alert: Johnson Fistel, LLP Reminds Investors of Deadline in the Class Action Lawsuit Against Diplomat Pharmacy, Inc.

  3/10/2019

  Shareholder rights law firm Johnson Fistel, LLP reminds investors that a class action lawsuit has been filed against Diplomat Pharmacy, Inc. on behalf of all purchasers of common stock during the period between February 26, 2018 through February 21, 2019, inclusive.

• EnvoyHealth to Offer Mango Health Mobile App

  3/4/2019

  EnvoyHealth partners with Mango Health in effort to help pharmaceutical manufacturer clients drive patient engagement and adherence.

• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Diplomat Pharmacy, Inc. - DPLO

  2/26/2019

  Pomerantz LLP is investigating claims on behalf of investors of Diplomat Pharmacy, Inc..